Different doses and courses of omalizumab for patients with chronic spontaneous urticaria: A systematic review with meta-analysis and trial sequential analysis

Background: The stability, efficacy, and safety of omalizumab at different doses and regimens for chronic spontaneous urticaria (CSU) are yet to be studied. Objective: A systematic review (SR) with meta-analysis (MA) and trial sequential analysis (TSA) was performed to assess the efficacy and safety...

Full description

Bibliographic Details
Main Authors: Haiyan Qin, MD, Xianjun Xiao, MD, PhD, Di Qin, MD, Peiwen Xue, MD, Huilin Liu, MD, Ying Li, MD, PhD, Yunzhou Shi, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:World Allergy Organization Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455124000292